HROW Key Statistics, Chart & Performance
The current stock price of HROW is 46.77 USD. In the past month the price increased by 32.04%. In the past year, price increased by 18.95%.
HROW Latest News, Press Relases and Analysis
HROW Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.13 | 959.08B | ||
| JNJ | JOHNSON & JOHNSON | 19.51 | 487.84B | ||
| MRK | MERCK & CO. INC. | 11.45 | 250.41B | ||
| PFE | PFIZER INC | 8.03 | 146.12B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.92 | 105.76B | ||
| ZTS | ZOETIS INC | 18.99 | 53.06B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.60B | ||
| VTRS | VIATRIS INC | 4.62 | 12.39B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 10.93B | ||
| CORT | CORCEPT THERAPEUTICS INC | 96.2 | 8.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.28B |
Related stock screener links
About HROW
Company Profile
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The firm offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Company Info
HARROW INC
1A Burton Hills Blvd, Suite 200
Nashville TENNESSEE 37205 US
CEO: Mark L. Baum
Employees: 382
Phone: 16157334731
HARROW INC / HROW FAQ
Can you describe the business of HARROW INC?
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The firm offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
What is the current price of HROW stock?
The current stock price of HROW is 46.77 USD. The price increased by 5.05% in the last trading session.
What is the dividend status of HARROW INC?
HROW does not pay a dividend.
What is the ChartMill rating of HARROW INC stock?
HROW has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is HROW stock listed?
HROW stock is listed on the Nasdaq exchange.
What do analysts say about HARROW INC (HROW) stock?
14 analysts have analysed HROW and the average price target is 72.13 USD. This implies a price increase of 54.22% is expected in the next year compared to the current price of 46.77.
What is HARROW INC worth?
HARROW INC (HROW) has a market capitalization of 1.73B USD. This makes HROW a Small Cap stock.
HROW Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to HROW. When comparing the yearly performance of all stocks, HROW is one of the better performing stocks in the market, outperforming 86.12% of all stocks.
HROW Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HROW. Both the profitability and the financial health of HROW get a neutral evaluation. Nothing too spectacular is happening here.
HROW Financial Highlights
Over the last trailing twelve months HROW reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 109.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.37% | ||
| ROE | -10.61% | ||
| Debt/Equity | 5.17 |
HROW Forecast & Estimates
14 analysts have analysed HROW and the average price target is 72.13 USD. This implies a price increase of 54.22% is expected in the next year compared to the current price of 46.77.
For the next year, analysts expect an EPS growth of 197.23% and a revenue growth 44.76% for HROW